PTC Therapeutics Inc. released a corporate presentation highlighting 2025 performance and key program updates. The company reported 2025 revenue of $831 million, including approximately $587 million in product revenue. It also provided 2026 guidance for product revenue of $700–$800 million and non-GAAP operating expenses of $680–$720 million. The presentation noted FDA and EMA approvals for Sephience and reported Q4 global Sephience revenue of $92 million ($81 million U.S., $11 million ex-U.S.), with 946 patients on commercial therapy worldwide and 1,134 U.S. patient start forms as of December 31, 2025. The company outlined plans to expand Sephience’s geographic footprint in 2026. Pipeline updates included votoplam in Huntington’s disease, with a global Phase 3 study (INVEST-HD) expected to be initiated by Novartis in the first half of 2026, targeting approximately 770 participants in more than 30 countries and using change in cUHDRS through 36 months as the primary endpoint. The presentation also summarized vatiquinone data in Friedreich’s ataxia, including results from the MOVE-FA study and long-term extension analyses. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on February 19, 2026, and is solely responsible for the information contained therein.